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Abstract
The combination of pegylated interferon (PEG-IFN) and ribavirin is the standard treatment for
chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of
interferon-stimulated genes (ISGs) in patients treated for hepatitis C virus (HCV) infection. In
order to further characterize the mechanisms of action of ribavirin, we examined the effect of
ribavirin treatment on ISG induction in cell culture. In addition, the effect of ribavirin on
infectious HCV cell culture systems was studied. Similar to interferon (IFN)-α, ribavirin potently
inhibits JFH-1 infection of Huh7.5.1 cells in a dose-dependent manner, which spans the
physiological concentration of ribavirin in vivo. Microarray analysis and subsequent quantitative
polymerase chain reaction assays demonstrated that ribavirin treatment resulted in the induction of
a distinct set of ISGs. These ISGs, including IFN regulatory factors 7 and 9, are known to play an
important role in anti-HCV responses. When ribavirin is used in conjunction with IFN-α,
induction of specific ISGs is synergistic when compared with either drug applied separately.
Direct up-regulation of these antiviral genes by ribavirin is mediated by a novel mechanism
different from those associated with IFN signaling and intracellular double-stranded RNA sensing
pathways such as RIG-I and MDA5. RNA interference studies excluded the activation of the Toll-
like receptor and nuclear factor κB pathways in the action of ribavirin.
Conclusion—Our study suggests that ribavirin, acting by way of a novel innate mechanism,
potentiates the anti-HCV effect of IFN. Understanding the mechanism of action of ribavirin would
be valuable in identifying novel antivirals
Ribavirin, a guanosine analog, demonstrates a broad spectrum of antiviral activity in tissue
culture against numerous DNA and RNA viruses. Currently, it is used in conjunction with
pegylated interferon (IFN)-α as standard treatment for chronic hepatitis C virus (HCV)
infection.2 Ribavirin has transient antiviral activity in patients with HCV when used as
monotherapy,3 but markedly improves treatment response when combined with IFN.4 Its
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role in improving treatment outcomes is well established, but the precise mechanism by
which it acts synergistically with IFN has remained elusive. In patients, ribavirin appears to
enhance the second and third phases of viral decay, thereby limiting relapse, particularly in
patients with suboptimal responses to IFN.5 Although several mechanisms of action have
been proposed for ribavirin’s antiviral activity, each with some experimental evidence, none
has been convincingly shown to explain the combined effect of ribavirin with IFN in HCV
antiviral therapy.6
There are five proposed mechanisms by which ribavirin exerts its antiviral activity.7 These
can be subdivided into direct and indirect mechanisms based on whether they directly
impact the virus life cycle. The direct mechanisms of action include ribavirin acting as a
mutagen through its incorporation into the HCV genome, subsequently resulting in error
catastrophe,8,9 and ribavirin as an inhibitor of the HCV RNA–dependent RNA
polymerase.10 There are three indirect mechanisms of action that have been proposed. First,
ribavirin is an inhibitor of the ionosine monophosphate dehydrogenase (IMPDH) enzyme,
resulting in depletion of intracellular guanosine pools, which are needed for efficient viral
replication.11,12 Ribavirin has also been shown to stimulate a T helper 1 antiviral response
that favors viral clearance.13 Lastly, ribavirin has recently been shown to modulate the
expression of interferon-stimulated genes (ISGs) in patients receiving a modified antiviral
treatment regimen with a loading dose of ribavirin monotherapy given before the initiation
of standard combination therapy and in a tissue culture model of respiratory syncytial virus
infection.14–16 When we examined gene expression patterns of patients treated with this
modified treatment regimen, we found that patients treated with ribavirin and pegylated
interferon (PEG-IFN) had a higher level of ISG induction than patients who received PEG-
IFN alone.14 Because ribavirin confers a significant therapeutic efficacy when given in
combination with IFN,4 we hypothesized that ribavirin may augment the activity of IFN by
interacting with its antiviral signaling cascade.
Type I IFNs are produced by most cells in the body in response to viral infection and other
cellular stressors. After its production, IFN-α and IFN-β act in an autocrine and paracrine
manner. Binding to the type I IFN receptor leads to activation of the Janus kinase–signal
transducer and activator of transcription (STAT) pathway, resulting in phosphorylated
STAT molecules translocating to the nucleus, combining with IFN regulatory factor (IRF) 9
to form a complex that binds to the IFN-sensitive response element, a promoter upstream of
a large number of genes collectively known as ISGs. It is through the action of these genes
that IFN-α is thought to exert its antiviral activity.17
Ultimately, the antiviral effect of ribavirin observed in HCV-infected patients may involve
multiple mechanisms. However, little attention has been focused on the fact that ribavirin
greatly enhances the clinical effect of IFN, and yet has minimal or no long-term antiviral
effect of its own.18 This suggests that ribavirin functions by modulating the IFN response.
Elucidating the interplay between these two agents will likely be important both for
understanding and potentially augmenting their clinical effects.
Patients and Methods
The complete Patients and Methods are provided in the Supporting Information.
Results
Up-Regulation of IRF7 and IRF9 by Ribavirin in Patients
We previously conducted a clinical study in patients with HCV to examine the mechanisms
of action of ribavirin in combination with PEG-IFN.14 Patients were separated into two
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cohorts. The first cohort received weight-based ribavirin monotherapy for 3 days before
starting standard antiviral treatment. Twenty-four hours after their first injection of PEG-
IFN, a liver biopsy was performed. The second cohort received PEG-IFN only and
underwent a liver biopsy 24 hours later (Fig. 1A). To further examine these results, gene
expression analysis revealed that IRF7 levels were higher in patients receiving ribavirin and
PEG-IFN than in those on PEG-IFN alone (Fig. 1B); furthermore, higher IRF7 messenger
RNA (mRNA) levels were present in patients who displayed a superior response to
treatment (Fig. 1C). In addition to IRF7, other ISGs such as IRF9 were found to be higher in
patients receiving combination therapy.14 To confirm the relevance of the microarray
results, we performed immunohistochemical analysis on the liver biopsy specimens and
found higher levels of IRF7 staining in patients receiving ribavirin and PEG-IFN than in
patients receiving PEG-IFN alone (Fig. 1D, E).
Up-Regulation of Select ISGs in Cultured Cells Treated with Ribavirin
In order to study ribavirin’s action further, we used tissue culture models to assess the effect
of ribavirin on mammalian cells with and without HCV infection. Microarray analysis of
uninfected human hepatoma (Huh7.5.1) cells19 treated with ribavirin for 24 hours
demonstrated that several ISGs, including IRF9 and ISG15, were induced by ribavirin
treatment (Fig. 1F). In this experiment, ribavirin also up-regulated IRF7 mRNA levels as
determined by quantitative polymerase chain reaction (qPCR) (data not shown). Because
ISGs are known to contribute to the antiviral activity of IFN,17 we next determined whether
ribavirin possessed antiviral activity against HCV using the JFH1 infectious clone in
Huh7.5.1 cells.20 Ribavirin exhibited dose-dependent antiviral activity against HCV (Fig.
2A). Similarly, IFN-α used at a dose of 100 U/mL displayed significant antiviral activity
that could be further increased by the addition of increasing doses of ribavirin (Fig. 2A).
Notably, the two antiviral compounds had different effects on gene expression. As expected,
IFN greatly up-regulated a host of classical ISGs (data not shown), whereas the effect of
ribavirin was more selective, affecting the expression of a subset of these genes (Fig. 1F).
IFN strongly induced RSAD2, but ribavirin had a minimal effect (Fig. 2B). In contrast,
ribavirin increased the levels of IRF7, IRF9, and ISG15 (Fig. 2C). These data show that
ribavirin induces a subset of ISGs and that the combined action of each agent has a potent
inhibitory effect on HCV.
Synergistic Induction of ISGs by Ribavirin and IFN-α Treatment
To further investigate ribavirin’s effect on gene expression, we performed dose-response
and time course experiments with ribavirin. Supporting Fig. 1A demonstrates the
reproducible up-regulation of IRF7 mRNA levels with increasing doses and length of
treatment with ribavirin. We observed similar results in ribavirin-treated HepG2 cells
(Supporting Fig. 1B). Because of the significant clinical benefit observed with the
combination of IFN-α and ribavirin, we specifically evaluated whether ribavirin and IFN-α
have a synergistic effect on gene expression in cultured cells. Treatment with IFN-α resulted
in maximal gene induction at approximately 8 hours with lower levels of mRNA observed at
24 hours after treatment (Supporting Fig. 2). Because ribavirin and IFN have distinct
kinetics with respect to gene induction, we chose to study gene expression after treatment
with each drug, alone or in combination at various concentrations, at their maximal point of
induction. IRF9 mRNA levels were extensively examined, because IRF9 was up-regulated
by both IFN-α and ribavirin (Fig. 2C). Fig. 3A demonstrates greater gene induction of IRF9
by the combination of IFN and ribavirin than either compound alone, in a concentration-
dependent manner, even at the lowest doses used (1 and 3 μg/mL). For example, IFN-α
treatment alone resulted in a 25-fold induction of IRF9 mRNA levels at a dose of 100 U/mL,
but when combined with 3 μg/mL of ribavirin, resulted in approximately 80-fold induction.
A normalized isobologram was generated from the qPCR data, and it demonstrated synergy
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as combinations plotted to the left of the corresponding line of additivity (Fig. 3B). We also
observed similar results for ISG15 mRNA levels after treatment with ribavirin and IFN and
confirmed the ability of ribavirin to increase ISG induction by IFN in Huh7.5.1 and Huh7
cells (Supporting Fig. 3).
Because ribavirin and IFN-α resulted in synergistic induction of IRF9 mRNA levels, we
next determined the effect of IRF9 on HCV replication using RNA interference (RNAi). As
a transfection and functional control, we used short interfering RNA (siRNA)-mediated
suppression of CD81, which resulted in decreased levels of HCV RNA (Fig. 3C).21 In
contrast, suppression of IRF9 levels by RNAi resulted in increased levels of HCV RNA,
illustrating an antiviral role for IRF9 on HCV replication. In addition, suppression of IRF9
levels abrogated ribavirin’s antiviral effect compared with the nontargeting control siRNA
(Fig. 3C). RNAi-mediated gene suppression was confirmed by qPCR for CD81 and IRF9
(Fig. 3D).
Because patients treated with combination therapy were already infected with HCV, we
hypothesized that the presence of virus may also contribute to an increased effect of
ribavirin and IFN-α on gene induction. Interestingly, high ISG levels have been observed in
liver biopsies obtained from HCV-infected patients and chimpanzees.14,22,23 To mimic the
effect seen in patients infected with HCV, we used polyinosinic:polycytidylic acid
[poly(I:C)], a double-stranded RNA viral mimetic, in conjunction with ribavirin and IFN.
We were able to detect low-level ISG induction by JFH1 in Huh7.5.1 cells in tissue culture
(Fig. 2B, C) as described.24 Supporting Fig. 4A shows the effect of transfected poly(I:C) on
gene induction with mRNA levels increasing over time for selected genes. Ribavirin,
poly(I:C), and IFN-α treatment had very little effect on IFN-β mRNA levels (Supporting
Fig. 4B). Poly(I:C) had a minimal effect on IFN-β expression because these cells harbor a
defective RIG-I pathway.25 However, the addition of ribavirin augmented the induction of
IFI44 and RSAD2 seen with poly(I:C) and/or IFN-α treatment separately or in combination
(Supporting Fig. 4C).
Ribavirin Up-Regulates ISGs Through a Novel Mechanism
To investigate the mechanism by which ribavirin affects gene transcription, we first
investigated whether de novo protein synthesis was required using cycloheximide, a
molecule commonly used to block protein synthesis.26,27 Addition of cycloheximide 1 hour
before ribavirin treatment did not block the induction of IRF7 mRNA levels, suggesting that
new protein synthesis was not required. However, the addition of cycloheximide alone
induced IRF7 expression, complicating the interpretation of this experiment (Fig. 4A). We
next determined whether treatment with MG132, a proteosome inhibitor,27,28 could block
the effect of ribavirin or cycloheximide on IRF7 induction. Indeed, treatment with MG132
greatly decreased the induction of IRF7 by either cycloheximide or ribavirin (Fig. 4A).
Similarly, MG132 inhibited the effect of both ribavirin and cycloheximide on induction of
IRF7, IRF9, and ISG15 (Fig. 4B). Together, these data suggest that a short-lived protein,
possibly a transcriptional repressor, may be involved in the regulation of IRF7 and other
ISGs and that ribavirin and cycloheximide may act on similar pathways.
Because one consequence of MG132 treatment is the inhibition of the nuclear factor κB
(NFκB)29 signaling pathway, we next investigated whether NFκB signaling was required
for the induction of IRF7 mRNA levels by ribavirin. siRNA-mediated suppression of the
NFκB signaling components I kappa B kinase (IKK) α and IKKγ resulted in a significant
decrease in their respective mRNA levels and functional activity; however, ribavirin was
equally effective in inducing IRF7 in these siRNA-treated cells (Fig. 5A, B). We have also
used siRNAs targeting the transcription factors NFκB1, NFκB2, and RELA and saw no
inhibition of ribavirin activity on gene induction (data not shown). Furthermore, Toll-like
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receptor 7 is involved in the recognition of guanosine analogues, an event that can lead to
the activation of NFκB.30 However, we did not observe any detectable reduction in ribavirin
activity in cells treated with siRNAs targeting TRIF and MyD88, critical adaptor molecules
implicated in Toll-like receptor signaling and subsequent NFκB activation (Supporting Fig.
5).31 We also used RNA interference to determine if IFN signal transduction and
intracellular double-stranded RNA sensing pathways such as RIG-I and MDA5 were
involved in ribavirin-stimulated gene induction.32 siRNAs targeting IPS1 and STAT1,
important signaling components of these pathways, had no effect (Fig. 6A–D). Therefore,
ribavirin-stimulated induction of ISGs is not sensitive to inhibition of the aforementioned
signaling pathways by siRNAs. In addition, we found that ribavirin was unable to stimulate
both IFN-sensitive response element and NFκB promoter luciferase constructs (data not
shown). Because both ribavirin and cycloheximide resulted in up-regulation of IRF7, IRF9,
and ISG15, we determined the effect of these two molecules on the mRNA levels of the type
I (α/β) and type III (IL28A, IL28B, and IL29) IFNs. Supporting Fig. 6A demonstrates that
neither molecule up-regulated any of these cytokines, which are induced by similar signaling
pathways.33 Furthermore, blocking type I IFN activity with a recombinant vaccinia virus-
encoded neutralizing protein, B18R, had no effect on ribavirin-stimulated gene induction
(Supporting Fig. 6B).
Effects of Guanosine Analogues on ISG Expression
Because ribavirin is a guanosine analogue (Fig. 7A), we next determined whether guanosine
itself could block ribavirin’s antiviral activity against the JFH1 infectious clone. We
observed minimal antiviral activity after guanosine treatment; however, there was a dose-
dependent reversal of ribavirin’s antiviral activity with concomitant addition of guanosine to
the cell culture media (Fig. 7B). We next determined whether guanosine itself (Fig. 7A)
could stimulate gene induction. Fig. 7C demonstrates up-regulation of IRF7, IRF9, and
ISG15 by ribavirin; however, guanosine treatment had no effect on gene induction. We next
determined whether addition of guanosine to the culture media could inhibit ribavirin-
induced gene induction. qPCR analysis of Huh7.5.1 cells treated with ribavirin and
guanosine clearly showed the ability of guanosine to reverse the effect of ribavirin on gene
induction for IRF7, IRF9, and ISG15 (Fig. 7C). We have also performed experiments with
the guanosine analogue loxoribine and saw no effect on ISG expression nor ribavirin
antiviral activity (data not shown).
To additionally confirm that the effects of ribavirin are not cell type–specific, we also
treated activated primary rat hepatic stellate cells with ribavirin. Activated hepatic stellate
cells are thought to be the cell type responsible for the deposition of collagen in an injured
liver,34 and ribavirin monotherapy has been shown to decrease liver inflammation as
demonstrated by decreased alanine aminotransferase levels and improved liver histology in
patients receiving ribavirin monotherapy.35 Furthermore, in our human study referenced
above,14 we noted a substantial reduction of markers of hepatic stellate activation by
ribavirin. Microarray analysis confirmed the induction of several ISGs, including OAS1,
MX2, IRF7, and IRF9 (Supporting Fig. 7A), demonstrating that ribavirin’s effects on gene
expression are not limited to hepatocyte-derived cells. Induction of IRF7 was also confirmed
by real-time PCR (Supporting Fig. 7B) in these samples.
Discussion
Our data suggest that ribavirin may exert its antiviral activity in patients treated with
combination therapy by potentiating the effect of IFN action on ISG induction, which results
in enhanced antiviral responses. Although we observed the induction of several antiviral
genes by ribavirin, IRF7 and IRF9 are of particular interest. Both IRF7 and IRF9 have been
shown to be critical for antiviral responses in mice through their roles in endogenous IFN
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production and signaling.36,37 Furthermore, IRF9 (also known as ISGF3G) has been shown
to have direct antiviral activity against HCV in tissue culture (Fig. 3C),38 and IRF7 mRNA
levels from peripheral blood mononuclear cells have been shown to correlate with responses
to antiviral therapy in HCV-infected patients.39 In addition to their direct antiviral effects,
IRF7 and IRF9 may be of particular importance because of their role in amplifying the IFN
signaling cascade. Improved IFN signaling through the up-regulation of these molecules
would have the potential to significantly improve the effects of PEG-IFN treatment.
We have observed that treatment of cells in tissue culture with ribavirin leads to a dose-
dependent induction of a subset of ISGs. This observation was unexpected given that the
induction of ISGs is a tightly regulated process usually occurring only during viral infections
and pathological states that result in the production of IFN.40 Furthermore, ribavirin was
also shown to have antiviral effects on JFH1 infection (Fig. 2) and on various HCV
replicon–containing cells12,41–43 when ribavirin was administered at similar doses used in
this study.43 Several studies have demonstrated that ribavirin’s beneficial effect on HCV
treatment outcomes is dose-dependent and that higher doses of ribavirin result in higher
response rates.44–47 During antiviral therapy, the levels of ribavirin achieved in the serum
are 1–4 μg/mL.48–50 Correspondingly, we have observed reproducible changes in gene
expression and synergistic effects on gene induction by the combination of ribavirin and IFN
with doses of ribavirin as low as 1 and 3 μg/mL in tissue culture, and these effects were
dose-dependent (Fig. 3A, B; Supporting Figs. 1 and 3).
Previous pharmacodynamic studies have shown that an extended dosing period (≈4 weeks)
is needed to reach steady-state blood concentration.51 Furthermore, the tissue concentration
of ribavirin may be substantially higher, because ribavirin tends to concentrate in certain
tissues. Indeed, several studies have shown that the intracellular concentration of ribavirin in
erythrocytes can reach over 100 times greater than that that found in plasma52,53 and that
hepatocytes have specific nucleoside transporters that facilitate uptake of ribavirin from
plasma.54 In this study, we used ribavirin at doses up to 100 μg/mL in infected or uninfected
cells for 24 hours in tissue culture experiments without any observable toxicity (Supporting
Fig. 8 and data not shown).
The up-regulation of ISGs by ribavirin may be due to the inhibition of a transcriptional
repressor. Other studies have shown that ISGs are under the control of transcriptional
repressors, and this may be an increasingly important mechanism for ISG regulation.55 Our
data also suggest that this repressor may be a short-lived protein degraded by the 26S
proteosome. Consequently, treatment with proteosome inhibitors stabilize this protein,
making cells resistant to the effect of ribavirin and cycloheximide on IRF7, IRF9, and
ISG15 (Fig. 4A, B). The addition of guanosine to the medium can also block ribavirin-
induced gene induction and antiviral activity in a dose-dependent fashion. The ability of
guanosine to block ribavirin activity may point to involvement of the IMPDH pathway.
IMPDH inhibition by ribavirin could induce guanosine depletion, and guanosine depletion
may lead to IRF7/IRF9 induction, which may explain why gene induction can be reversed
by supplementation of guanosine to the culture medium. Indeed, IMPDH inhibitors have
shown antiviral activity in cell culture models of HCV infection.12,56 However, at this time,
no IMPDH inhibitors have obtained U.S. Food and Drug Administration approval for the
treatment of hepatitis C, indicating that this may not be the only mechanism by which
ribavirin exerts its antiviral activity.57,58 Additional studies will be needed to determine if
IMPDH inhibitors can effect ISG induction by IFN in cell culture models of virus infection
as well as in patients.
Recognition of ribavirin’s ability to induce ISGs may explain ribavirin’s antiviral activity
against numerous viruses and will facilitate the discovery of a class of therapeutic agents
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that possess more potent antiviral activity by specifically regulating antiviral genes.
Importantly, ribavirin’s effect on ISG regulation appears to be IFN-independent (Fig. 6;
Supporting Figs. 4B and 6). Several lines of evidence support the IFN-independent activity
of ribavirin. First, we have not observed the full spectrum of ISG induction after ribavarin
administration seen following IFN treatment (Figs. 1F and 2B). Second, RNAi against
signaling components, which are critical for IFN production and activity, did not affect
ribavirin-stimulated gene induction (Fig. 6A–D). Finally, we did not observe gene induction
of either the type I or type III IFNs following ribavirin treatment (Supporting Fig. 6A). This
may be particularly relevant for viruses such as HCV that have developed numerous
strategies to circumvent the IFN system.59 This class of molecules, like ribavirin, may thus
be able to potentiate the antiviral effects of IFN through synergistic induction of antiviral
genes using different molecular mechanisms.
Although it was originally thought that the development of agents specifically targeting
steps in the HCV life cycle would soon make IFN and ribavirin obsolete, emerging data
suggest that this may not be the case. Because direct antivirals quickly select for resistant
strains, it appears that PEG-IFN will likely be required to achieve an optimal response.
Importantly, recent trials with HCV protease inhibitors have shown that ribavirin is also
needed to prevent viral relapse.60 Therefore, the search for alternative ribavirin-like
molecules in potentiating IFN action and for use in combination with specifically targeted
antiviral agents remains a promising approach in the therapy of HCV-infected patients.
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Acknowledgments
Supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, and in part by a National Institutes of Health K24 mentoring award
DK066144 (to M. W. F.).
Abbreviations
HCV hepatitis C virus
IFN interferon
IKK I kappa B kinase
IRF interferon regulatory factor
ISG interferon-stimulated gene
mRNA messenger RNA
NFκB nuclear factor κB
PEG-IFN pegylated interferon
poly(I:C) polyinosinic:polycytidylic acid
qPCR quantitative polymerase chain reaction
RNAi RNA interference
siRNA short interfering RNA
STAT signal transducer and activator of transcription
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IRF7 expression in liver biopsy samples from HCV-infected patients and induction of ISGs
by ribavirin. (A) Treatment regimen of clinical protocol (IRB-UNC GCRC 1728). (B) IRF7
mRNA levels, determined by way of qPCR, in liver biopsies from patients receiving PEG-
IFN (n = 5) versus PEG-IFN plus ribavirin (n = 6) (P = 0.035). (C) qPCR analysis of IRF7
mRNA induction by dividing on-treatment over pretreatment mRNA levels in liver biopsies
from patients demonstrating a slow virological response (SR, n = 5) and a rapid virological
response (RR, n = 6) (P = 0.004). Virological response was defined by posttreatment viral
kinetics. (D) IRF7 staining in liver biopsies. Immunoglobulin G and IRF7 antibodies (Santa
Cruz Biotechnology) were used to stain untreated liver biopsies. (E) Quantification of IRF7
staining using ImageJ software (P = 0.08). (F) Microarray analysis demonstrating gene
induction of several ISGs after treatment with ribavirin for 24 hours at a dose of 100 μg/mL
in uninfected Huh7.5.1 cells. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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Antiviral activity of ribavirin and IFN-α on HCV infection and subsequent gene induction.
(A) qPCR analysis of viral RNA after 28 hours of infection with JFH1 (multiplicity of
infection = 0.5) in Huh7.5.1. with ribavirin (1, 10, 100 μg/mL) and IFN-α (100 U/ mL)
separately or in combination for 24 hours. Numbers above the error bars represent HCV
RNA copies × 104. (B,C) qPCR of mRNA levels after 24 hours of treatment with ribavirin
(100 μg/mL) and IFN-α (100 U/mL) for RSAD2 (B) and IRF7, IRF9, and ISG15 (C) genes
in cells with and without JFH1 infection. Data represent experiments performed in triplicate.
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Synergistic up-regulation of IRF9 mRNA levels following ribavirin and IFN-α combination
treatment and effect of IRF9 suppression on HCV infection and antiviral effects of ribavirin.
(A) qPCR analysis of IRF9 induction after treatment with ribavirin (1, 3, 10, 30 μg/mL for
24 hours) and IFN-α (1, 3, 10, 30, 100 U/mL for 8 hours) in Huh7.5.1 cells. (B) Normalized
isobologram demonstrating synergy between ribavirin and IFN-α on IRF9 mRNA levels for
14 combinations of the two drugs generated with Calcusyn software. (C) Effect of siRNA-
mediated suppression, performed as described in the Materials and Methods, of IRF9 and
CD81 on JFH1 replication (multiplicity of infection = 0.5 for 40 hours) with or without
ribavirin (100 μg/mL for 36 hours). Nonspecific siRNA was used as a baseline control.
Numbers above error bars represent HCV RNA copies × 106. (D) qPCR analysis of CD81
and IRF9 mRNA levels following siRNA mediated gene suppression. (E) qPCR analysis of
ISG15 mRNA levels following treatment with IFN-α (100 U/mL for 24 hours) in cells
treated with nonspecific and IRF9 siRNAs. Data represent experiments performed in
triplicate.
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MG132 blocks gene induction by cycloheximide and ribavirin. qPCR analysis of (A) IRF7
and (B) IRF7, IRF9, and ISG15 mRNA levels after treatment with ribavirin (100 μg/mL for
24 hours), cycloheximide (10 μg/mL for 25 hours), and MG132 (10 μM for 25 hours) in
Huh7.5.1 cells.
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Gene induction by ribavirin does not involve NFκB signaling. (A) qPCR analysis of IRF7
mRNA levels in Huh7.5.1 cells first treated with siRNAs targeting IKKα and IKKγ and
then treated with or without ribavirin (100 mg/mL) for 24 hours (with quantification of
siRNA-mediated gene suppression). (B) NFκB promoter luciferase activity, 24 hours after
plasmid transfection, in cells first treated with siRNAs for 3 days targeting IKKα and IKKγ
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Gene induction by ribavirin does not involve RIG-I–like helicase or IFN signaling pathways.
(A) qPCR analysis of IRF7 mRNA levels in Huh7.5.1 cells first treated with siRNAs
targeting IPS1 and then treated with or without ribavirin. (B) qPCR analysis of RSAD2
mRNA levels following transfection of poly(I:C) (6 μg/mL for 8 hours) in cells treated with
nonspecific and IPS1 siRNAs. (C) qPCR analysis of IRF7 mRNA levels in Huh7.5.1 cells
first treated with siRNAs targeting STAT1 and then treated with or without ribavirin. (D)
qPCR analysis of RSAD2 mRNA levels following treatment with IFN-α (100 U/mL) in
cells treated with nonspecific and STAT1 siRNAs. Data represent experiments performed in
triplicate.
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Guanosine does not stimulate ISG induction but can block ribavirin-stimulated gene
induction and antiviral effects. (A) Chemical structures of guanosine and ribavirin. (B)
qPCR analysis of viral RNA after 40 hours infection with JFH1 (multiplicity of infection =
0.5) in Huh7.5.1 cells. Four hours post infection, cells were treated with guanosine (1, 10,
100 μg/mL) and ribavirin (100 μg/mL) separately or in combination for 36 hours. Numbers
above error bars represent HCV RNA copies × 106. (C–E) qPCR analysis of mRNA levels
after treatment with guanosine (1, 10, 100 μg/mL for 24 hours) and ribavirin (100 μg/mL
for 24 hours) separately or in combination for IRF7(C), IRF9 (D), and ISG15 (E). Data
represent experiments performed in triplicate.
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